Our Mission is to improve the lives of patients suffering from difficult to treat cancers, with a focus on pancreatic cancer through novel therapies that prime and boost their immune response and improve the performance of their cancer treatment, enabling them to live longer.
Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immunomodulator. IMM-101 induces a broad immune response, modulating the innate and adaptive immune systems with a potential to complement existing therapies, including targeted immunotherapies and cytotoxics. IMM-101 has the potential to work in difficult-to-treat tumours, including those that have been considered immunologically ‘cold’.
Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine.
Latest from Immodulon
Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101
Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement significant oncology drug development experience of Immodulon’s new management...
Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer
Richard Couch, formerly at Celgene, appointed as Chief Technology Officer Owen Vaughan, formerly at Taiho Oncology, appointed as Chief Regulatory Officer Appointments add decades of industry experience to support advancement of IMM-101 into a pivotal trial in...
Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer
Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal trial in...